341 related articles for article (PubMed ID: 27150690)
1. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes.
Schwartz PJ; Woosley RL
J Am Coll Cardiol; 2016 Apr; 67(13):1639-1650. PubMed ID: 27150690
[TBL] [Abstract][Full Text] [Related]
2. Molecular predictors of drug-induced prolongation of the QT interval.
Dilaveris PE
Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):105-18. PubMed ID: 15853698
[TBL] [Abstract][Full Text] [Related]
3. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
4. [Drug induced QT prolongation].
Altmann D; Eggmann U; Ammann P
Wien Klin Wochenschr; 2008; 120(5-6):128-35. PubMed ID: 18365152
[TBL] [Abstract][Full Text] [Related]
5. Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death.
Wolbrette DL
Curr Cardiol Rep; 2004 Sep; 6(5):379-84. PubMed ID: 15306095
[TBL] [Abstract][Full Text] [Related]
6. A polygenic risk score for the QT interval is an independent predictor of drug-induced QT prolongation.
Simon ST; Lin M; Trinkley KE; Aleong R; Rafaels N; Crooks KR; Reiter MJ; Gignoux CR; Rosenberg MA
PLoS One; 2024; 19(6):e0303261. PubMed ID: 38885227
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced QT prolongation and sudden death.
Del Rosario ME; Weachter R; Flaker GC
Mo Med; 2010; 107(1):53-8. PubMed ID: 20222297
[TBL] [Abstract][Full Text] [Related]
8. [Risk management with regard to QT-prolonging drugs].
Aengevaeren VL; van Gastel MDA; Fleuren HWHA; Helsloot I; Beukema RJ; Kramers C
Ned Tijdschr Geneeskd; 2024 Jun; 168():. PubMed ID: 38888230
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.
Shah RR
Drug Saf; 2004; 27(3):145-72. PubMed ID: 14756578
[TBL] [Abstract][Full Text] [Related]
10. Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome.
Darbar D; Kimbrough J; Jawaid A; McCray R; Ritchie MD; Roden DM
J Am Coll Cardiol; 2008 Feb; 51(8):836-42. PubMed ID: 18294569
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of drug induced QT interval prolongation.
Ponte ML; Keller GA; Di Girolamo G
Curr Drug Saf; 2010 Jan; 5(1):44-53. PubMed ID: 20210718
[TBL] [Abstract][Full Text] [Related]
12. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
Pearson EC; Woosley RL
Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):747-53. PubMed ID: 15918160
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced torsades de pointes in patients aged 80 years or more.
Paran Y; Mashav N; Henis O; Swartzon M; Arbel Y; Justo D
Anadolu Kardiyol Derg; 2008 Aug; 8(4):260-5. PubMed ID: 18676301
[TBL] [Abstract][Full Text] [Related]
14. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
[TBL] [Abstract][Full Text] [Related]
15. Drugs causing prolongation of QT interval and torsades de pointes.
CMAJ; 1998 Jan; 158(1):103-4, 107-8. PubMed ID: 9475921
[No Abstract] [Full Text] [Related]
16. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug.
Badshah A; Janjua M; Younas F; Halabi AR; Cotant JF
Am J Med Sci; 2009 Aug; 338(2):164-6. PubMed ID: 19680025
[TBL] [Abstract][Full Text] [Related]
17. Citalopram induced torsade de pointes, a rare life threatening side effect.
Kanjanauthai S; Kanluen T; Chareonthaitawee P
Int J Cardiol; 2008 Dec; 131(1):e33-4. PubMed ID: 17919753
[TBL] [Abstract][Full Text] [Related]
18. Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation.
Kirchhof P; Franz MR; Bardai A; Wilde AM
J Am Coll Cardiol; 2009 Jul; 54(2):143-9. PubMed ID: 19573731
[TBL] [Abstract][Full Text] [Related]
19. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
Arbel Y; Swartzon M; Justo D
Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
[TBL] [Abstract][Full Text] [Related]
20. Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.
Mok NS; Lo YK; Tsui PT; Lam CW
J Cardiovasc Electrophysiol; 2005 Dec; 16(12):1375-7. PubMed ID: 16403073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
